# 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

> **NCT00763568** · PHASE2 · COMPLETED · sponsor: **Romark Laboratories L.C.** · enrollment: 40 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Nitazoxanide
- **BIOLOGICAL:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT00763568
- **Lead sponsor:** Romark Laboratories L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00763568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00763568, "4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00763568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*